Cover Image

Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT‐CN study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Lin Zhao, Hong Chen, Zhifeng Cheng, Hongwei Jiang, Yibing Lu, Jianzhong Xiao, Xinhua Xiao, Yuanyuan Li, Yuan Yuan, Xiaoying Li
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Obesity
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial
by: Lin Zhao, et al.
Published: (2025)

Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
by: Beverly G. Tchang, et al.
Published: (2025)

Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials
by: Deborah B. Horn, et al.
Published: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
by: Michelle Look, et al.
Published: (2025)

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial
by: Koutaro Yokote, et al.
Published: (2025)

Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight”
Published: (2025)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
by: Alpana P. Shukla, et al.
Published: (2025)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
by: Domenica M. Rubino, et al.
Published: (2025)

Correction to “Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS‐AP‐combo and SURPASS‐3”
Published: (2026)

Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
by: Rodolfo J. Galindo, et al.
Published: (2025)

Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J‐mono and J‐combo studies
by: Kazuya Fujihara, et al.
Published: (2024)

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
by: Brandon K. Bergman, et al.
Published: (2025)

Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J‐mono post hoc analysis
by: Masato Yoneda, et al.
Published: (2025)

Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
by: Theresa Hunter Gibble, et al.
Published: (2025)

Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli‐D study
by: Juan Liu, et al.
Published: (2025)

From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT ‐ MMO
by: Naveed Sattar
Published: (2025)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN
by: Deborah B. Horn, et al.
Published: (2025)

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
by: Jheng‐Yan Wu, et al.
Published: (2025)

Associations of body size and morphology with cardiometabolic health in children: the contribution of genetic factors
by: Karri Silventoinen, et al.
Published: (2024)

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT ‐1 Over 176 Weeks
by: Hiddo J. L. Heerspink, et al.
Published: (2026)

Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
by: Linong Ji, et al.
Published: (2024)

Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
by: Evgenia Gourgari, et al.
Published: (2025)

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial
by: Yasushi Ishigaki, et al.
Published: (2026)

Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
by: Meredith M. Hoog, et al.
Published: (2025)

Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo
by: Jianhua Ma, et al.
Published: (2024)

Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
by: Shanshan Hu, et al.
Published: (2024)

Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
by: Theresa Hunter Gibble, et al.
Published: (2025)

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT
by: Thomas A. Wadden, et al.
Published: (2026)

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
by: Wenying Yang, et al.
Published: (2024)

Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
by: Weijun Gu, et al.
Published: (2025)

Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
by: Leili Gao, et al.
Published: (2024)

Association between weight‐adjusted‐waist index and incident carotid atherosclerosis in the general adult population in Chinese communities: Evidence from the REACTION cohort study
by: Qingzheng Wu, et al.
Published: (2025)

Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data‐driven cluster analysis: A post‐hoc analysis of imeglimin clinical trial data
by: Katsuhiko Hagi, et al.
Published: (2024)

Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR‐T1D study
by: Stacey L. Simon, et al.
Published: (2024)

Anthropometry for predicting cardiometabolic disease risk factors in adolescents
by: Luyu Xie, et al.
Published: (2024)

Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo
by: Yuqian Bao, et al.
Published: (2024)

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
by: Daniel G. K. Rasmussen, et al.
Published: (2024)

Association of body roundness index with cardiovascular disease and all‐cause mortality among Chinese adults
by: Hong Lin, et al.
Published: (2025)

Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2
by: Zhiyuan Feng, et al.
Published: (2025)

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
by: Djordje S. Popovic, et al.
Published: (2024)